<html>

    <head>
  <meta charset="utf-8">
  <title>Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimers disease | Research Group at Uppsala University</title>
  <meta content="width=device-width, initial-scale=1" name="viewport">
  <meta content="Webflow" name="generator">
  <link href="/css/normalize.css" rel="stylesheet" type="text/css">
  <link href="/css/webflow.css" rel="stylesheet" type="text/css">
  <link href="/css/caramba.webflow.css?1710325047" rel="stylesheet" type="text/css">
  <script src="https://ajax.googleapis.com/ajax/libs/webfont/1.4.7/webfont.js"></script>
  <script type="text/javascript">
    WebFont.load({
      google: {
        families: ["Ubuntu:300,300italic,400,400italic,500,500italic,700,700italic","Raleway:regular,500,600,700,800,900"]
      }
    });
  </script>
  <script src="/js/modernizr.js" type="text/javascript"></script>
  <link href="/img/logos/caramba_header_logo.png" rel="shortcut icon" type="image/x-icon">
  <link href="/img/logos/caramba_header_logo.png" rel="apple-touch-icon">
  <script>
    (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
    (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
    m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
    })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

    ga('create', 'UA-86146183-1', 'auto');
    ga('send', 'pageview');
  </script>
</head>


    
  <div class="section-header" id="section-header">
    <div class="section-header-container w-container">
      <div class="navbar w-nav" data-animation="default" data-collapse="medium" data-contain="1" data-doc-height="1" data-duration="400" data-no-scroll="1">
        <div class="navbar-container w-container">
          <a class="navbar-brand w-nav-brand" href="/">
              <img class="navbar-logo" src="/img/logos/rect205.png" height="50">
          </a>
          <div class="navbar-menubutton w-nav-button">
            <div class="w-icon-nav-menu"></div>
          </div>
          <a class="navbar-uulogo-link" href="https://www.medsci.uu.se/caramba/" target="_blank"><img class="navbar-uulogo-img" src="/img/logos/uulogo_64x64.png"></a>
          <nav class="navbar-menu w-nav-menu" role="navigation" style="float: right">
              
              <a class="navbar-link w-nav-link" href="/project/">Projects</a>
              
              <a class="navbar-link w-nav-link" href="/people/">People</a>
              
              <a class="navbar-link w-nav-link" href="/facility/">Facility</a>
              
              <a class="navbar-link w-nav-link" href="/publication/">Publications</a>
              
              
              
              <a class="navbar-link w-nav-link" href="/education/">Education</a>
              
              <a class="navbar-link w-nav-link" href="/about/">About</a>
              
          </nav>
        </div>
      </div>
    </div>
  </div>

              <div>
          <div class="section-content-container w-container content">

        <h1 style="font-size: 1.4em">Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimers disease</h1>
        <p><a href="/publication">&larr; Back to publications</a></p>

        <p>Published: 2022-08-24</p>

        <h4>Formatted citation</h4>
        <p>
            Giannisis A, Al-Grety A, Carlsson H, Patra K, Twohig D, Sando SB, Lauridsen C, Berge G, Grøntvedt GR, Bråthen G, White LR, Kultima K, Nielsen HM..
            <a href="http://dx.doi.org/10.1186/s13195-022-01058-9" target="_blank">Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimers disease</a>.
            <br><em>Alzheimers Res Ther</em>.
             (2022).
            DOI: <a href="http://dx.doi.org/10.1186/s13195-022-01058-9" target="_blank">10.1186/s13195-022-01058-9</a>
            
        </p>
        <h4>Abstract</h4>
        <p>BACKGROUND: Low levels of plasma apolipoprotein E (apoE) and presence of the APOE ε4 allele are associated with an increased risk of Alzheimers disease (AD). Although the increased risk of AD in APOE ε4-carriers is well-established, the protein levels have received limited attention. METHODS: We here report the total plasma apoE and apoE isoform levels at baseline from a longitudinally (24xa0months) followed cohort including controls (nu2009=u200939), patients with stable amnestic mild cognitive impairment during 24xa0months follow up (MCI-MCI, nu2009=u200930), patients with amnestic MCI (aMCI) that during follow-up were clinically diagnosed with AD with dementia (ADD) (MCI-ADD, nu2009=u200928), and patients with AD with dementia (ADD) at baseline (ADD, nu2009=u200928). We furthermore assessed associations between plasma apoE levels with cerebrospinal fluid (CSF) AD biomarkers and α-synuclein, as well as both CSF and plasma neurofilament light chain (NfL), YKL-40 and kallikrein 6. RESULTS: Irrespective of clinical diagnosis, the highest versus the lowest apoE levels were found in APOExa0ε2/ε3 versus APOExa0ε4/ε4 subjects, with the most prominent differences exhibited in females. Total plasma apoE levels were 32% and 21% higher in the controls versus MCI-ADD and ADD patients, respectively. Interestingly, MCI-ADD patients exhibited a 30% reduction in plasma apoE compared to MCI-MCI patients. This decrease appeared to be associated with brain amyloid-β (Aβ42) pathology regardless of disease status as assessed using the Amyloid, Tau, and Neurodegeneration (A/T/N) classification. In addition to the association between low plasma apoE and low levels of CSF Aβ42, lower apoE levels were also related to higher levels of CSF total tau (t-tau) and tau phosphorylated at Threonine 181 residue (p-tau) and NfL as well as a worse performance on the mini-mental-state-examination. In MCI-ADD patients, low levels of plasma apoE were associated with higher levels of CSF α-synuclein and kallikrein 6. No significant correlations between plasma apoE and the astrocytic inflammatory marker YKL40 were observed. CONCLUSIONS: Our results demonstrate important associations between low plasma apoE levels, Aβ pathology, and progression from aMCI to a clinical ADD diagnosis.</p>

            </div>
</div>

      <div class="section-footer">
    <div class="section-footer-container w-container">
        
        <div class="footer-text">
            <p>
            <strong>CARAMBA Research Group</strong><br>
            Department of Medical Sciences<br>
            Uppsala University, Sweden<br>
            GitHub: <a href="https://github.com/caramba-uu">github.com/caramba</a>
            </p>
        </div>
    </div>
  </div>

  <script src="https://ajax.googleapis.com/ajax/libs/jquery/2.2.0/jquery.min.js" type="text/javascript"></script>
  <script src="/js/webflow.js" type="text/javascript"></script>
  
</body>
</html>

